235 related articles for article (PubMed ID: 30036346)
1. Lofexidine (Lucemyra) for opioid withdrawal.
Med Lett Drugs Ther; 2018 Jul; 60(1551):115-117. PubMed ID: 30036346
[No Abstract] [Full Text] [Related]
2. Expanded table: Some drugs for management of opioid withdrawal symptoms.
Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
[No Abstract] [Full Text] [Related]
3. Management of opioid withdrawal symptoms.
Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
[No Abstract] [Full Text] [Related]
4. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
5. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
Doughty B; Morgenson D; Brooks T
Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.
Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW;
J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine for the management of opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2009 Jul; (3):CD002025. PubMed ID: 19588330
[TBL] [Abstract][Full Text] [Related]
9. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
[TBL] [Abstract][Full Text] [Related]
12. FDA approves nonopioid medication for managing opioid withdrawal.
Traynor K
Am J Health Syst Pharm; 2018 Jul; 75(13):927. PubMed ID: 29941528
[No Abstract] [Full Text] [Related]
13. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Gish EC; Miller JL; Honey BL; Johnson PN
Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
[TBL] [Abstract][Full Text] [Related]
14. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Carnwath T; Hardman J
Drug Alcohol Depend; 1998 May; 50(3):251-4. PubMed ID: 9649979
[TBL] [Abstract][Full Text] [Related]
15. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
Kahn A; Mumford JP; Rogers GA; Beckford H
Drug Alcohol Depend; 1997 Jan; 44(1):57-61. PubMed ID: 9031821
[TBL] [Abstract][Full Text] [Related]
16. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
[TBL] [Abstract][Full Text] [Related]
17. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.
Bearn J; Gossop M; Strang J
Drug Alcohol Depend; 1998 May; 50(3):227-32. PubMed ID: 9649976
[TBL] [Abstract][Full Text] [Related]
18. Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms.
Bryce C
Am Fam Physician; 2019 Mar; 99(6):392-394. PubMed ID: 30874408
[No Abstract] [Full Text] [Related]
19. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial.
Beswick T; Best D; Bearn J; Gossop M; Rees S; Strang J
Am J Addict; 2003; 12(4):295-305. PubMed ID: 14504022
[TBL] [Abstract][Full Text] [Related]
20. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
